K. Jacobs

Isolation and characterization of genomic and cDNA clones of human erythropoietin

E. Fritsch, A. Mufson, C. Shoemaker, 1985, Nature.

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

S. Rutella, J. Dipersio, P. Chevallier, 2020, Blood.

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Pyridoxine deficiency in the human infant.

K. Jacobs, L. E. Holt, S. Snyderman, 1953, The Journal of clinical nutrition.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

S. Rutella, J. Dipersio, M. Jongen‐Lavrencic, 2020 .

Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)

Sung-Bae Kim, W. Gradishar, E. Rock, 2021 .

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia

I. Aldoss, K. Jacobs, S. Forman, 2023, Haematologica.